The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man
Open accessThe DOI matches its Crossref record.
Abstract
Opioid drugs act on specific receptors which are principally classified into μ, δ and κ subtypes. Spiradoline (U‐62066E) is a κ‐selective agent which has been shown to possess potent anti‐nociceptive effects but does not show cross tolerance with morphine. We have assessed the neuroendocrine effects of spiradoline in healthy volunteers with two doses (1.6 and 4.0 μg kg−1, i.m.) of the compound. Six male non‐smokers aged 19–27 years were studied by use of a randomized, double‐blind three‐limb placebo‐controlled cross‐over design. Blood was taken from an in‐dwelling venous cannula basally and at 15 min intervals for 2 h for determination of serum cortisol, prolactin, growth hormone (GH) and catecholamines. Psychological function was assessed by the Stanford Sleepiness Scale (SSS) and the Addiction Research Centre Inventory (ARCI) administered before the medication and at 35 min, 1 h 25 min and 2 h afterwards. Cardiovascular variables were recorded at 10 min intervals. Results were analysed by analysis of variance. Spiradoline showed a significant (P<0.05) dose‐dependent increase in free water clearance, as predicted for a κ‐opioid agonist. It also caused a dose‐dependent stimulation of prolactin, (increment over baseline for higher dose 214%), GH (433%) and cortisol (215%) release (P<0.05). There were no significant drug‐related changes in plasma catecholamines, blood pressure, pulse or psychological variables. We have therefore confirmed that κ‐opioids increase free‐water clearance and may participate in the stimulation of prolactin and GH release. In contrast to μ and δ‐opioid agonists, this novel κ‐agonist stimulates cortisol release in man. British Journal of Pharmacology (1997) 120, 781–784; doi:10.1038/sj.bjp.0700971
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
“More recent studies found gender differences in the response to some of these drugs (401), and a preferential activation of the opioid receptors (402).”
BackgroundDynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Kreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Peckys, D., & Landwehrmeyer, G. B. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00251-6 · Cited by 278
Role of kappa-opioid receptors in stress and anxiety-related behavior
Van’t Veer, A., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 257
Metadata
- Authors
- Ur, E., Wright, D. M., Bouloux, P. M. G., & Grossman, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1997-02
- Volume
- 120
- Issue
- 5
- Pages
- 781-784
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1992094129
- Cited by
- 83
- References
- 0
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man. https://app.cochat.ai/papers/10.1038/sj.bjp.0700971
- The paper
- Ur, E., Wright, D. M., Bouloux, P. M. G., & Grossman, A. (1997). The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0700971
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.